QUEST (12+ years), TRAVERSE OLE (12+ years)

DUPIXENT offered up to ~3 years of breathing relief: 310 mL improvement in FEV₁ at Week 96 in the DUPIXENT/DUPIXENT group (n=447) from 1.78 L at baseline in the parent study for patients enrolled from QUEST (overall exposed population, TRAVERSE OLE study, secondary endpoint).^9,a,b

Results are descriptive. There are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.

Patients with baseline blood EOS ≥300 cells/μL in QUEST experienced sustained breathing relief at Week 52: a 470 mL improvement from baseline in pre-bronchodilator FEV₁ with DUPIXENT 200 mg Q2W + SOC (n=264) vs 170 mL with placebo + SOC (n=148) (secondary endpoint).^1,11

At Week 12 in patients with no biomarker requirement: 320 mL improvement from baseline in pre-bronchodilator FEV₁ with DUPIXENT 200 mg Q2W + SOC (n=631) vs 180 mL with placebo + SOC (n=317) (LSM difference: 140 mL [95% CI: 80, 190 mL]) (ITT population, QUEST, primary endpoint)^1,9